This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demierre, M.-F. Articles by Nathanson, L. Search for Related Content PubMed PubMed Citation Articles by Demierre, M.-F. Articles by Nathanson, L.

Chemoprevention of Melanoma: An Unexplored Strategy

Marie-France Demierre, Larry Nathanson

From the Boston University School of Medicine, Boston, MA; and Skin Oncology Program, Boston; and Oncology Consultants, Cambridge, MA.

Address reprint requests to Marie-France Demierre, MD, Skin Oncology Program, Boston Medical Center, 720 Harrison Ave, DOB 801A, Boston, MA 02118; email: mariefrance.demierre{at}bmc.org.

The incidence and mortality of melanoma has continued to increase steeply—faster than most other preventable cancers in the United States. Current sun protection strategies have yet to reduce this increased incidence and mortality. Chemoprevention, defined as the use of natural or synthetic agents to delay, reverse, suppress, or prevent premalignant molecular or histologic lesions from progressing to invasive cancer, has become an important area in cancer research. Melanoma, with its associated risk factors and its known precursors or premalignant lesions, should lend itself well to chemoprevention. Prerequisites for this research should include determination of the molecular mechanisms of ultraviolet (UV) melanomagenesis; use of animal models to test candidate prevention agents; use of molecular and histologic markers as surrogate end point markers; collection of epidemiological, basic science, or in vitro data on potential chemoprevention candidate drugs; and selection of a high-risk patient population in which to carry out clinical chemoprevention trials. Preliminary data available in all these areas are reviewed. Possible mechanisms and molecular targets for the chemoprevention of UV-induced melanoma are discussed. This recent information should stimulate research in the chemoprevention of melanoma.

Supported in part by the Carl J. Herzog Foundation (to M.F.D.).

This article has been cited by other articles:

				M. Grabacka, P. M. Plonka, K. Urbanska, and K. Reiss Peroxisome Proliferator-Activated Receptor {alpha} Activation Decreases Metastatic Potential of Melanoma Cells In vitro via Down-Regulation of Akt. Clin. Cancer Res., May 15, 2006; 12(10): 3028 - 3036. [Abstract] [Full Text] [PDF]

				K. M. Dale, C. I. Coleman, N. N. Henyan, J. Kluger, and C. M. White Statins and Cancer Risk: A Meta-analysis JAMA, January 4, 2006; 295(1): 74 - 80. [Abstract] [Full Text] [PDF]

				S. Yang, K. Irani, S. E. Heffron, F. Jurnak, and F. L. Meyskens Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor Mol. Cancer Ther., December 1, 2005; 4(12): 1923 - 1935. [Abstract] [Full Text] [PDF]

				M.-F. Demierre, C. Chung, D. R. Miller, and A. C. Geller Early Detection of Thick Melanomas in the United States: Beware of the Nodular Subtype Arch Dermatol, June 1, 2005; 141(6): 745 - 750. [Abstract] [Full Text] [PDF]

				H. TAKEUCHI, A. FUJIMOTO, and D. S.B. HOON Detection of Mitochondrial DNA Alterations in Plasma of Malignant Melanoma Patients Ann. N.Y. Acad. Sci., June 1, 2004; 1022(1): 50 - 54. [Abstract] [Full Text] [PDF]

				F. L. Meyskens Jr., P. J. Farmer, and H. Anton-Culver Etiologic Pathogenesis of Melanoma: A Unifying Hypothesis for the Missing Attributable Risk Clin. Cancer Res., April 15, 2004; 10(8): 2581 - 2583. [Full Text] [PDF]

				E. A. Collisson, C. Kleer, M. Wu, A. De, S. S. Gambhir, S. D. Merajver, and M. S. Kolodney Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells Mol. Cancer Ther., October 1, 2003; 2(10): 941 - 948. [Abstract] [Full Text]

				F. L. Meyskens Jr. Management of Human Melanoma: What Has the Last Decade Wrought? Oncologist, October 1, 2003; 8(5): 448 - 450. [Full Text] [PDF]